Stock PAR PARADIGM BIOPHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Market Closed - Australian S.E.
Other stock markets
 02:10:11 2024-05-03 am EDT 		5-day change 1st Jan Change
0.245 AUD -10.91% Intraday chart for Paradigm Biopharmaceuticals Limited -14.04% -42.35%
Apr. 19 Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program MT
Feb. 28 Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program
MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint
MT
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%
MT
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer
MT
Paradigm Biopharmaceuticals Raising AU$30 Million for Clinical Trial
MT
Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately
CI
Paradigm Biopharmaceuticals Validates Cartilage Preservation in Knee Osteoarthritis Trial
MT
Paradigm Biopharmaceuticals Confirms Effectivity of Pain Medication in Osteoarthritis Trial
MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Paradigm Biopharmaceuticals Validates Efficacy of Anti-Inflammatory Medication in Canine Trial
MT
Australia’s Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up
AQ
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up
CI
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study
CI
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial
MT
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial
CI
Starpharma Appoints CFO
MT
Paradigm Biopharmaceuticals Names Interim CFO
MT
Paradigm Biopharmaceuticals Limited Announces the Change of Chief Financial Officer
CI
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PAR Stock
  4. News Paradigm Biopharmaceuticals Limited